Bristol Myers Squibb disclosed detailed Phase 3 results showing its cereblon E3 ligase modulator mezigdomide more than doubled progression-free survival in relapsed or refractory multiple myeloma in the SUCCESSOR-2 trial. BMS reported an 18-month average PFS in the mezigdomide arm versus 8.3 months in the comparator, cutting the risk of progression or death by 52%—with side effects higher but described as manageable. Separately, teclistamab delivered landmark international Phase 3 readouts in MajesTEC-9 for patients relapsing after initial therapy, with the program designed to deepen remissions through bispecific activity. Together, the updates reflect continued momentum for myeloma bispecifics and cereblon-based therapies aimed at improving depth and durability of response.